Keros Therapeutics, Inc. Experiences Revision in Stock Evaluation Amidst Market Challenges

Keros Therapeutics, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone a valuation adjustment. The company's current P/E ratio stands at 145, indicating a significant premium compared to typical industry metrics. Its price-to-book value is recorded at 0.84, while the EV to EBIT and EV to EBITDA ratios are 10.43 and 11.94, respectively. Notably, Keros has a PEG ratio of 1.42, suggesting a moderate growth expectation relative to its earnings.
In terms of performance, Keros has faced challenges, particularly over the past year, with a stock return of -73.78%, contrasting sharply with the S&P 500's gain of 19.89% during the same period. The company's returns over longer periods also reflect a downward trend, with a 5-year return of -72.63% compared to the S&P 500's 109.18%.

When compared to its peers, Keros Therapeutics stands out with a relatively high valuation despite its performance struggles. Competitors like Day One Biopharmaceuticals and Revance Therapeutics are categorized as risky, highlighting the competitive landscape and the challenges Keros faces in maintaining its market position.